Known targets — ChEMBL curated mechanism
ACHESCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Gluconic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.95 |
| ▸ | PDE4A | P27815 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | CA4 | P22748 | 2/20 | 0.34 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gluconic Acid SCHEMBL27990997 | 1.00 | LMNA (0.95) | LMNAPDE4AL3MBTL1USP2SLCO1B1 | |
| Gluconic Acid SCHEMBL30213455 | 0.98 | LMNA (1.00) | LMNAPDE4AL3MBTL1USP2SLCO1B1 | |
| Gluconic Acid SCHEMBL31213255 | 0.98 | LMNA (1.00) | LMNAPDE4AL3MBTL1USP2SLCO1B1 | |
| Gluconic Acid SCHEMBL29431841 | 0.98 | LMNA (1.00) | LMNAPDE4AL3MBTL1USP2SLCO1B1 | |
| Gluconic Acid SCHEMBL3768836 | 0.98 | LMNA (0.91) | LMNAPDE4AL3MBTL1USP2SLCO1B1 | |
| Gluconic Acid SCHEMBL2572507 | 0.98 | LMNA (1.00) | LMNAPDE4AL3MBTL1USP2SLCO1B1 | |
| Gluconic Acid SCHEMBL9456606 | 0.98 | LMNA (0.91) | LMNAPDE4AL3MBTL1USP2SLCO1B1 | |
| Gluconic Acid SCHEMBL5065814 | 0.98 | LMNA (1.00) | LMNAPDE4AL3MBTL1USP2SLCO1B1 | |
| Gluconic Acid SCHEMBL23640 | 0.98 | LMNA (1.00) | LMNAPDE4AL3MBTL1USP2SLCO1B1 | |
| Gluconic Acid SCHEMBL35424 | 0.98 | LMNA (0.91) | LMNAPDE4AL3MBTL1USP2SLCO1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090304816-A1 | METHOD AND COMPOSITION FOR TREATING AND DIAGNOSING RESTLESS LEGS SYNDROME | CEREUSCIENCE AB (SE) | 2009-12-10 | — | — | US | claimed |
| EP-1973551-A1 | METHOD AND COMPOSITION FOR TREATING AND DIAGNOSING RESTLESS LEGS SYNDROME | Cereuscience AB (SE) | 2008-10-01 | — | — | EP | claimed |
| EP-1827418-A2 | COMPOSITIONS INCLUDING IRON | Drugtech Corporation (US) | 2007-09-05 | — | — | EP | claimed |
| EP-1827419-A2 | METHODS AND COMPOSITIONS FOR ENHANCING IRON ABSORPTION | Drugtech Corporation (US) | 2007-09-05 | — | — | EP | claimed |
| WO-2007073325-A1 | METHOD AND COMPOSITION FOR TREATING AND DIAGNOSING RESTLESS LEGS SYNDROME | CEREUSCIENCE AB (SE) | 2007-06-28 | — | — | WO | claimed |
| WO-2006068697-A2 | COMPOSITIONS INCLUDING IRON | DRUGTECH CORPORATION (US) | 2006-06-29 | — | — | WO | claimed |
| WO-2006068729-A2 | METHODS AND COMPOSITIONS FOR ENHANCING IRON ABSORPTION | DRUGTECH CORPORATION (US) | 2006-06-29 | — | — | WO | claimed |
| US-20060134227-A1 | Compositions including iron | DRUGTECH CORPORATION | 2006-06-22 | — | — | US | claimed |
| WO-2003086321-A2 | MODIFIED RELEASE MINERALS | DRUGTECH CORPORATION (US) | 2003-10-23 | — | — | WO | claimed |
| US-20030190355-A1 | Modified release minerals | DRUGTECH CORPORATION | 2003-10-09 | — | — | US | claimed |
| CN-119488480-A | Novel iron compositions and methods of making and using the same | 雷尼布斯治疗公司 | 2025-02-21 | — | — | CN | disclosed |
| CN-116636620-B | Black egg white peptide composition and application thereof | 南昌大学 | 2025-02-14 | — | — | CN | disclosed |
| WO-2024263116-A1 | A STABLE CAPSULE COMPOSITION WITH GASTRO-RESISTANT PELLETS FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA | ILKO ILAC SANAYI VE TICARET A.S. (TR) | 2024-12-26 | — | — | WO | disclosed |
| CN-113825496-B | Novel iron compositions and methods of making and using the same | 雷尼布斯治疗公司 | 2024-09-27 | — | — | CN | disclosed |
| WO-2023119230-A1 | COAGULATION PATHWAY AND NICOTINAMIDE-ADENINE DINUCLEOTIDE PATHWAY MODULATING COMPOSITIONS AND METHODS OF THEIR USE | L'OREAL (FR) | 2023-06-29 | — | — | WO | disclosed |
| WO-2006068697-A2 | COMPOSITIONS INCLUDING IRON | DRUGTECH CORPORATION (US) | 2006-06-29 | — | — | WO | disclosed |
| US-20060134227-A1 | Compositions including iron | DRUGTECH CORPORATION | 2006-06-22 | — | — | US | disclosed |
| US-20050037065-A1 | NUTRITIONAL FORMULATIONS | DRUGTECH CORPORATION (US) | 2005-02-17 | — | — | US | disclosed |
| WO-2003086321-A2 | MODIFIED RELEASE MINERALS | DRUGTECH CORPORATION (US) | 2003-10-23 | — | — | WO | disclosed |
| US-20030190355-A1 | Modified release minerals | DRUGTECH CORPORATION | 2003-10-09 | — | — | US | disclosed |